Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vupanorsen - Ionis Pharmaceuticals/Pfizer

Drug Profile

Vupanorsen - Ionis Pharmaceuticals/Pfizer

Alternative Names: AKCEA ANGPTL3 LRx; IONIS ANGPTL3 LRx; ISIS 703802 salt; ISIS-703802; PF 07285557; Vupanorsen sodium

Latest Information Update: 28 Sep 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ionis Pharmaceuticals
  • Developer Akcea Therapeutics; Ionis Pharmaceuticals; Pfizer
  • Class Antihyperglycaemics; Antihyperlipidaemics; Antisense oligonucleotides; Hepatoprotectants
  • Mechanism of Action ANGPTL3 protein inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Dyslipidaemias; Familial partial lipodystrophy; Hyperlipoproteinaemia type I; Non-alcoholic fatty liver disease; Type 2 diabetes mellitus
  • Phase I/II Hyperlipoproteinaemia type IIa
  • Discontinued Hypertriglyceridaemia

Most Recent Events

  • 28 Sep 2023 No recent reports of development identified for phase-I development in Hyperlipoproteinaemia-type-I(In the elderly, In volunteers, In adults) in Japan (SC, Injection)
  • 08 Feb 2022 Discontinued - Phase-I for Hypertriglyceridaemia (In volunteers) in China (SC)
  • 08 Feb 2022 Discontinued - Phase-II for Hypertriglyceridaemia in USA, Canada (SC)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top